What is the main purpose of this 8-K filing?

The main purpose of this Form 8-K filing is to disclose material definitive agreements related to the establishment of executive compensation for the year 2006, including salaries, stock options, restricted stock awards, and performance-based bonus targets for key officers of WellPoint, Inc.

How is executive compensation tied to company performance?

Executive compensation is significantly tied to company performance through the annual bonus structure, which is based on achieving specified levels of diluted earnings per share (EPS). The Compensation Committee also considers other factors such as synergy goals, strategic business unit operating gain, membership growth, and individual performance when setting final bonus awards.

What are the vesting schedules for the stock options and restricted stock awards?

The 2006 stock option grants vest in six equal semi-annual installments over three years, beginning September 1, 2006. The 2006 restricted stock awards vest in three equal annual installments over three years, beginning March 1, 2007.

ELV 8-K: Material Agreements

Q: Are there any special benefits for the CEO?

Yes, on March 1, 2006, the Compensation Committee approved an increase in benefits payable under the WellPoint, Inc. Directed Executive Compensation (DEC) Program for the President and Chief Executive Officer. This program allows executives to tailor certain benefits using a combination of Cash and Core Credits, with the CEO receiving increased amounts.

Summary

This Form 8-K filed by WellPoint, Inc. (now Elevance Health, Inc.) on March 3, 2006, primarily details material definitive agreements related to executive compensation. The Compensation Committee of the Board of Directors established salary, stock option grants, restricted stock awards, and annual bonus targets for key executive officers for the year 2006. These compensation packages are designed to align executive interests with company performance, particularly through performance-based bonuses tied to diluted earnings per share, synergy goals, and strategic business unit operating gains. Key executives, including CEO Larry C. Glasscock, received significant compensation packages. The filing also outlines the terms for vesting of stock options and restricted stock awards, with options vesting over three years and restricted stock vesting over three years starting in 2007. Additionally, an amendment to the Directed Executive Compensation (DEC) Program for the President and Chief Executive Officer was approved, allowing for tailored executive benefits. Investors should note that these decisions reflect the company's strategy to attract and retain top talent while incentivizing performance in a competitive healthcare landscape.

Key Highlights

1WellPoint, Inc. (now Elevance Health) established 2006 compensation packages for its executive officers on March 1, 2006.
2Compensation includes base salary, stock option grants, restricted stock awards, and annual bonus targets tied to performance.
3CEO Larry C. Glasscock receives a base salary of $1,300,000, 320,000 stock options, 40,000 restricted stock units, and a 140% bonus target.
4Stock options have an exercise price of $76.59 and vest semi-annually over three years starting September 1, 2006.
5Restricted stock awards vest annually over three years starting March 1, 2007.
6Annual bonuses are performance-based, primarily linked to diluted earnings per share (EPS) targets, with provisions for synergy goals, operating gain, and individual performance.
7The Directed Executive Compensation (DEC) Program was amended for the CEO, increasing Cash and Core Credits for tailored executive benefits.

Elevance Health, Inc. 8-K Report, Material Agreement (Mar 3, 2006)

Summary

Key Highlights

Frequently Asked Questions